BACKGROUND Since venous drainage in acute arterial
ischemic stroke has not been thoroughly researched, we evaluate the effect of
argatroban, a selective
direct thrombin inhibitor, as a
therapy to increase the rate of basal vein Rosenthal (BVR) drainage and improve patients' post-
stroke outcomes. MATERIAL AND METHODS In this multicenter clinical trial, 60 eligible patients at 4.5 to 48 hours after the
stroke onset were recruited. After being randomly allocated into 2 groups, they were treated with standard
therapy either alone or with
argatroban. RESULTS Compared to the contralateral brain hemisphere, the mean flow velocity (MFV) in BVR drainage was significantly reduced in the
stroke-afflicted ipsilateral hemisphere.
After treatment with
argatroban for 7 days, the MFV from BVR of the ipsilateral hemisphere in the
argatroban treated group was significantly increased when compared to the control group. At 90 days after the onset of
stroke, the MFV of BVR in the ipsilateral hemisphere was similar in both groups. Compared with controls, the
argatroban-treated patients had smaller lesions from baseline to 7 days.
Argatroban also improved National Institutes of Health
Stroke Scale (NIHSS) scores on day 7 after the onset of
stroke. Furthermore, the
argatroban group's neurological functions were superior to those of their untreated counterparts after 90 days. No difference was found in the incidence of adverse reactions between the 2 groups. CONCLUSIONS These observations indicate that vein drainage change may contribute to the acute phase of
brain edema and the outcomes of
ischemic stroke patients.